Spectral Domain OCT Predictors of Visual Acuity in the Study of COmparative Treatments for REtinal Vein Occlusion 2: SCORE 2 Report 15.


Journal

Ophthalmology. Retina
ISSN: 2468-6530
Titre abrégé: Ophthalmol Retina
Pays: United States
ID NLM: 101695048

Informations de publication

Date de publication:
10 2021
Historique:
received: 16 09 2020
revised: 07 12 2020
accepted: 21 12 2020
pubmed: 30 12 2020
medline: 8 1 2022
entrez: 29 12 2020
Statut: ppublish

Résumé

To evaluate the association between baseline demographic and spectral domain OCT (SD-OCT) features with visual acuity (VA) in the Study of COmparative Treatments for REtinal Vein Occlusion 2 (SCORE2) over 2 years. Post hoc analysis of prospective clinical trial data. A total of 362 SCORE2 participants with macular edema secondary to central retinal (CRVO) or hemiretinal vein occlusion (HRVO). Spectral domain OCT volume scans were assessed at the SCORE2 reading center at baseline, month 01 (M01), month 06 (M06), month 12 (M12), and month 24 (M24) for central subfield thickness (CST), subretinal fluid, intraretinal fluid, vitreoretinal interface abnormalities, disorganization of retinal inner layers (DRIL), and ellipsoid zone (EZ) within the central subfield (CSF). Visual acuity at M06, M12, and M24. Mean baseline age was 68.9 years. Mean VA at M01 was 63.2 letters, and CST was 299.7 μm. At M01, subretinal fluid was seen in 28.5% intraretinal fluid in 67.2%, DRIL was seen in 73.8%, mostly within the CSF, and the EZ was absent in 9.8 and patchy in 31.7%. In multivariate analysis including all M01 demographics and SD-OCT parameters and their association with VA at M06, M12, and M24, VA at M01 remained significant across all time points up to M24 (P < 0.001). In this 2-year follow-up of eyes that were treated with both per protocol and off protocol for RVO, VA at M01 was an important predictor of long-term vision and change in vision. Establishing predictors of visual recovery helps identify causes for poor responders to treatment in patients with RVO.

Identifiants

pubmed: 33373715
pii: S2468-6530(20)30503-0
doi: 10.1016/j.oret.2020.12.016
pmc: PMC8233398
mid: NIHMS1658181
pii:
doi:

Substances chimiques

Angiogenesis Inhibitors 0
Recombinant Fusion Proteins 0
aflibercept 15C2VL427D
Bevacizumab 2S9ZZM9Q9V
Receptors, Vascular Endothelial Growth Factor EC 2.7.10.1

Types de publication

Clinical Trial, Phase III Comparative Study Journal Article Multicenter Study Randomized Controlled Trial Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

991-998

Subventions

Organisme : NEI NIH HHS
ID : P30 EY016665
Pays : United States
Organisme : NEI NIH HHS
ID : U10 EY023533
Pays : United States
Organisme : NEI NIH HHS
ID : U10 EY023529
Pays : United States
Organisme : NEI NIH HHS
ID : U10 EY023521
Pays : United States
Organisme : NEI NIH HHS
ID : UG1 EY023533
Pays : United States

Informations de copyright

Copyright © 2020 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.

Références

Ophthalmology. 2010 Jun;117(6):1124-1133.e1
pubmed: 20381871
JAMA Ophthalmol. 2017 Jun 1;135(6):639-649
pubmed: 28492860
BMC Ophthalmol. 2019 Jan 8;19(1):11
pubmed: 30621653
Retina. 2017 Sep;37(9):1710-1722
pubmed: 27984548
Ophthalmology. 2017 Feb;124(2):245-256
pubmed: 27863843
Ophthalmology. 2010 Jun;117(6):1094-1101.e5
pubmed: 20430447
JAMA Ophthalmol. 2019 Jan 1;137(1):38-46
pubmed: 30286219
Ophthalmol Retina. 2020 Jan;4(1):67-76
pubmed: 31669329
Am J Ophthalmol. 2017 Oct;182:160-167
pubmed: 28837790
Ophthalmology. 2009 Mar;116(3):504-12
pubmed: 19167078
Ophthalmology. 2012 May;119(5):1024-32
pubmed: 22440275
Ophthalmol Retina. 2018 Aug;2(8):836-841
pubmed: 30221215
JAMA. 2017 May 23;317(20):2072-2087
pubmed: 28492910
Trans Am Ophthalmol Soc. 2000;98:133-41; discussion 141-3
pubmed: 11190017
PLoS One. 2013 Dec 26;8(12):e82922
pubmed: 24386127
Am J Ophthalmol. 2016 Nov;171:47-52
pubmed: 27567889
JAMA Ophthalmol. 2019 Jan 1;137(1):46-47
pubmed: 30286233
J Thromb Haemost. 2015 Jul;13(7):1254-63
pubmed: 25894549
Invest Ophthalmol Vis Sci. 2018 Jul 2;59(8):3503-3510
pubmed: 30025093
Int J Ophthalmol. 2017 Apr 18;10(4):605-612
pubmed: 28503435
Ophthalmol Retina. 2019 Jan;3(1):83-92
pubmed: 30929820
JAMA Ophthalmol. 2014 Nov;132(11):1309-16
pubmed: 25058813
Ophthalmol Retina. 2018 Nov;2(11):1125-1132
pubmed: 30511035
Br J Ophthalmol. 2013 Mar;97(3):278-84
pubmed: 23298885
Arch Ophthalmol. 1996 Oct;114(10):1243-7
pubmed: 8859084
Ophthalmologica. 2018;240(4):229-234
pubmed: 30089307
Ophthalmology. 2010 Jun;117(6):1102-1112.e1
pubmed: 20398941
Retina. 2018 Mar;38(3):559-568
pubmed: 28248827
Ophthalmology. 2010 Jun;117(6):1113-1123.e15
pubmed: 20430446

Auteurs

Tyler Etheridge (T)

Department of Ophthalmology and Visual Sciences, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.

Barbara Blodi (B)

Department of Ophthalmology and Visual Sciences, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.

Neal Oden (N)

The Emmes Company, LLC, Rockville, Maryland.

Paul Van Veldhuisen (P)

The Emmes Company, LLC, Rockville, Maryland.

Ingrid U Scott (IU)

Departments of Ophthalmology and Public Health Sciences, Penn State College of Medicine, Hershey, Pennsylvania.

Michael S Ip (MS)

Doheny Eye Institute, University of California Los Angeles Stein Eye Institute, Los Angeles, California.

Mihai Mititelu (M)

Department of Ophthalmology and Visual Sciences, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.

Amitha Domalpally (A)

Department of Ophthalmology and Visual Sciences, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin. Electronic address: domalpally@wisc.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH